Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Shares Continue to Climb as CEO Laukien s Buying Spree Jumps to $1.1M Worth of Stock

NEW YORk, May 18 (GenomeWeb News) - Bruker Biosciences CEO Frank Laukien bought more than $1.1 million worth of his company's shares since May 10, sending the stock up 12.7 percent to $3.99 in mid-afternoon trading today from their close of $3.54 on May 10.

 

According to Insidercow.com, which tracks insider trading at public companies, Laukien bought 277,430 shares of Bruker stock at prices between $3.60 and $3.00 per share between May 10 and May 17.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.